RU2748806C2 - Средства для лечения инфекции вируса гепатита в (hbv) и их применение - Google Patents

Средства для лечения инфекции вируса гепатита в (hbv) и их применение Download PDF

Info

Publication number
RU2748806C2
RU2748806C2 RU2018142797A RU2018142797A RU2748806C2 RU 2748806 C2 RU2748806 C2 RU 2748806C2 RU 2018142797 A RU2018142797 A RU 2018142797A RU 2018142797 A RU2018142797 A RU 2018142797A RU 2748806 C2 RU2748806 C2 RU 2748806C2
Authority
RU
Russia
Prior art keywords
sequence
seq
shmir
effector
nucleic acid
Prior art date
Application number
RU2018142797A
Other languages
English (en)
Russian (ru)
Other versions
RU2018142797A3 (enExample
RU2018142797A (ru
Inventor
Тин МАО
Дэвид СЬЮХИ
Original Assignee
Бенитек Байофарма Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бенитек Байофарма Лимитед filed Critical Бенитек Байофарма Лимитед
Publication of RU2018142797A publication Critical patent/RU2018142797A/ru
Publication of RU2018142797A3 publication Critical patent/RU2018142797A3/ru
Application granted granted Critical
Publication of RU2748806C2 publication Critical patent/RU2748806C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
RU2018142797A 2016-05-05 2017-05-05 Средства для лечения инфекции вируса гепатита в (hbv) и их применение RU2748806C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662332245P 2016-05-05 2016-05-05
US62/332,245 2016-05-05
PCT/AU2017/050413 WO2017190197A1 (en) 2016-05-05 2017-05-05 Reagents for treatment of hepatitis b virus (hbv) infection and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2021113126A Division RU2021113126A (ru) 2016-05-05 2017-05-05 Средства для лечения инфекции вируса гепатита в (hbv) и их применение

Publications (3)

Publication Number Publication Date
RU2018142797A RU2018142797A (ru) 2020-06-05
RU2018142797A3 RU2018142797A3 (enExample) 2020-09-10
RU2748806C2 true RU2748806C2 (ru) 2021-05-31

Family

ID=60202535

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2018142797A RU2748806C2 (ru) 2016-05-05 2017-05-05 Средства для лечения инфекции вируса гепатита в (hbv) и их применение
RU2021113126A RU2021113126A (ru) 2016-05-05 2017-05-05 Средства для лечения инфекции вируса гепатита в (hbv) и их применение

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2021113126A RU2021113126A (ru) 2016-05-05 2017-05-05 Средства для лечения инфекции вируса гепатита в (hbv) и их применение

Country Status (11)

Country Link
US (2) US11535851B2 (enExample)
EP (1) EP3452595A4 (enExample)
JP (1) JP2019514401A (enExample)
KR (1) KR102358280B1 (enExample)
CN (1) CN109415733A (enExample)
AU (2) AU2017260580B2 (enExample)
CA (1) CA3023185A1 (enExample)
PH (1) PH12018502320A1 (enExample)
RU (2) RU2748806C2 (enExample)
SG (1) SG11201809753YA (enExample)
WO (1) WO2017190197A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019514401A (ja) * 2016-05-05 2019-06-06 ベニテック バイオファーマ リミテッド Ｂ型肝炎ウイルス（ｈｂｖ）感染を治療するための試薬およびその使用
WO2020100994A1 (ja) * 2018-11-16 2020-05-22 公益財団法人東京都医学総合研究所 Ｂ型肝炎ウイルスの複製阻害組成物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2217161C2 (ru) * 1997-08-26 2003-11-27 Сосьете Де Консей Де Решерш Э Д'Аппликасьон Сьентифик (С.К.Р.А.С.) Способ лечения вирусного гепатита
WO2008147430A2 (en) * 2006-10-11 2008-12-04 Nucleonics, Inc. Microrna-formatted multitarget interfering rna vector constructs and methods of using the same
WO2013003520A1 (en) * 2011-06-30 2013-01-03 Arrowhead Research Corporation Compositions and methods for inhibiting gene expression of hepatitis b virus
WO2015030616A2 (en) * 2013-09-02 2015-03-05 Instytut Chemii Bioorganicznej Pan Nucleic acid molecule, expression cassette, expression vector, eukaryotic host cell, induction method of rna interference in eukaryotic host and use of nucleic acid molecule in therapy of diseases induced by expansion of trinucleotide cag repeats

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030206887A1 (en) 1992-05-14 2003-11-06 David Morrissey RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
EP1412371B1 (en) * 2001-07-12 2016-02-24 University of Massachusetts IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING
CN1257284C (zh) 2003-03-05 2006-05-24 北京博奥生物芯片有限责任公司 一种体外阻断乙肝病毒表达的方法
US8575327B2 (en) * 2003-06-12 2013-11-05 Alnylam Pharmaceuticals, Inc. Conserved HBV and HCV sequences useful for gene silencing
EP2316942B1 (en) 2004-12-22 2021-04-21 Alnylam Pharmaceuticals, Inc. Conserved hbv and hcv sequences useful for gene silencing
CN101603042B (zh) * 2008-06-13 2013-05-01 厦门大学 可用于乙型肝炎病毒感染治疗的rna干扰靶点
JP2012528588A (ja) * 2009-06-05 2012-11-15 ソル，ダイ‐ウ 単一またはマルチ標的遺伝子を抑制するマルチ−シストロンｓｈＲＮＡ発現カセット
US20130267429A1 (en) * 2009-12-21 2013-10-10 Lawrence Livermore National Security, Llc Biological sample target classification, detection and selection methods, and related arrays and oligonucleotide probes
KR20180110186A (ko) 2010-10-28 2018-10-08 베니텍 바이오파마 리미티드 Hbv 치료
WO2013159109A1 (en) 2012-04-20 2013-10-24 Isis Pharmaceuticals, Inc. Modulation of hepatitis b virus (hbv) expression
DK2922554T3 (en) * 2012-11-26 2022-05-23 Modernatx Inc Terminalt modificeret rna
WO2014117050A2 (en) 2013-01-26 2014-07-31 Mirimus, Inc. Modified mirna as a scaffold for shrna
CN103088026A (zh) 2013-02-01 2013-05-08 中国人民解放军军事医学科学院放射与辐射医学研究所 抗乙型肝炎病毒人工miRNA及其组合
HK1251010A1 (zh) 2015-05-06 2019-01-18 Benitec IP Holdings Inc. 用於治疗乙型肝炎病毒(hbv)感染的试剂及用途
JP2019514401A (ja) * 2016-05-05 2019-06-06 ベニテック バイオファーマ リミテッド Ｂ型肝炎ウイルス（ｈｂｖ）感染を治療するための試薬およびその使用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2217161C2 (ru) * 1997-08-26 2003-11-27 Сосьете Де Консей Де Решерш Э Д'Аппликасьон Сьентифик (С.К.Р.А.С.) Способ лечения вирусного гепатита
WO2008147430A2 (en) * 2006-10-11 2008-12-04 Nucleonics, Inc. Microrna-formatted multitarget interfering rna vector constructs and methods of using the same
WO2013003520A1 (en) * 2011-06-30 2013-01-03 Arrowhead Research Corporation Compositions and methods for inhibiting gene expression of hepatitis b virus
WO2015030616A2 (en) * 2013-09-02 2015-03-05 Instytut Chemii Bioorganicznej Pan Nucleic acid molecule, expression cassette, expression vector, eukaryotic host cell, induction method of rna interference in eukaryotic host and use of nucleic acid molecule in therapy of diseases induced by expansion of trinucleotide cag repeats

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ely, A., Naidoo, T., Arbuthnot, P. Efficient silencing of gene expression with modular trimeric Pol II expression cassettes comprising microRNA shuttles. Nucleic Acids Research, 2009, 37(13), e91-e91. doi:10.1093/nar/gkp446. *

Also Published As

Publication number Publication date
AU2017260580B2 (en) 2022-07-28
RU2018142797A3 (enExample) 2020-09-10
KR102358280B1 (ko) 2022-02-07
SG11201809753YA (en) 2018-12-28
JP2019514401A (ja) 2019-06-06
KR20190003756A (ko) 2019-01-09
RU2018142797A (ru) 2020-06-05
PH12018502320A1 (en) 2022-01-24
US11535851B2 (en) 2022-12-27
CA3023185A1 (en) 2017-11-09
AU2017260580A1 (en) 2018-11-22
WO2017190197A1 (en) 2017-11-09
US20230093951A1 (en) 2023-03-30
RU2021113126A (ru) 2021-08-20
EP3452595A4 (en) 2020-02-19
EP3452595A1 (en) 2019-03-13
US20190338285A1 (en) 2019-11-07
CN109415733A (zh) 2019-03-01
AU2022241489A1 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
US8691967B2 (en) Multiple promoter expression cassettes for simultaneous delivery of RNAi agents
US20210177885A1 (en) Reagents for treatment of hepatitis b virus (hbv) infection and use thereof
US12312583B2 (en) MicroRNA-based logic gates and uses thereof
JP2023062092A (ja) 眼咽頭型筋ジストロフィー（ｏｐｍｄ）を治療するための試薬及びその使用
US20230093951A1 (en) Reagents for treatment of hepatitis b virus (hbv) infection and use thereof
JP7441174B2 (ja) Ｂ型肝炎ウイルスの複製阻害組成物
during Human Targets of Small Interfering RNA
HK1162044A (en) Multiple promoter expression cassettes for simultaneous delivery of rnai agents